Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

US market

- PMLiVE

Type 2 diabetes can be reversed in just four months, say researchers

A controlled diet and a strict exercise regime could help cure type 2 diabetes

- PMLiVE

Merck & Co and Pfizer take aim at diabetes with trio of new drugs

File ertugliflozin-based products with EU and US regulators

- PMLiVE

Novo Nordisk’s North American head Jakob Riis to leave

He will be replaced by Doug Langa

- PMLiVE

AZ gets US approval for diabetes combo Qtern

Wins licensing for Onglyza/Farxiga dual-therapy after rejection by the FDA in 2015

- PMLiVE

Denmark pitches for EMA, with help from ex Novo Nordisk CEO

Lars Rebien Sørensen to serve as special envoy to promote Danish candidacy

- PMLiVE

Novo Nordisk invests £115m in Oxford diabetes unit

But Danish pharma company admitted Brexit had made it a harder decision

- PMLiVE

J&J pondering future of diabetes device assets

Three diabetes care subsidiaries under review as firm forecasts measured 2017 sales

Novo signs personalised digital health deal in diabetes

Will work with Glooko on jointly-developed and branded solutions

Eli Lilly HQ

Lilly streamlines and culls leadership roles

Merges Europe and emerging markets interests and expands diabetes and oncology

Sanofi reception

Sanofi launches insulin combo Soliqua in US

Diabetes drug available in pharmacies for $127 per 300 unit pen ahead of Novo Nordisk's Xultophy

- PMLiVE

Pfizer/Opko’s long-acting growth hormone misses mark in trial

Previously forecast as a blockbuster product, hGH-CTP fails to show significant change

- PMLiVE

EU citizens are living longer, but not always in good health

Report finds huge inequalities between and within countries despite higher life expectancy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links